<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5033">
  <stage>Registered</stage>
  <submitdate>21/05/2015</submitdate>
  <approvaldate>21/05/2015</approvaldate>
  <nctid>NCT02453711</nctid>
  <trial_identification>
    <studytitle>Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus</studytitle>
    <scientifictitle>Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-001540-38</secondaryid>
    <secondaryid>NN9536-4153</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolism and Nutrition Disorder</healthcondition>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - semaglutide
Treatment: drugs - liraglutide
Treatment: drugs - placebo

Experimental: A:Semaglutide 0,05 mg - 

Experimental: B:Semaglutide 0,1 mg - dose 0.05 or 0.1 mg with dose escalation every fourth week

Experimental: C:Semaglutide 0,2 mg - dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week

Experimental: D:Semaglutide 0,3 mg - dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week

Experimental: E:Semaglutide 0,4 mg - dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week

Experimental: F:Semaglutide 0,3 mg - dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week

Experimental: G:Semaglutide 0,4 mg - dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week

Active Comparator: H_Liraglutide 3,0 mg - dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week

Placebo Comparator: I:Placebo - 


Treatment: drugs: semaglutide
Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Treatment: drugs: liraglutide
Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Treatment: drugs: placebo
Once-daily subcutaneous (s.c., under the skin) administration.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relative change in body weight (%)</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion (%) of subjects with weight loss of equal to or above 5% of baseline body weight</outcome>
      <timepoint>At 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion (%) of subjects with weight loss of equal to or above 10% of baseline body weight</outcome>
      <timepoint>At 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body weight (kg)</outcome>
      <timepoint>Weeks 0-52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glycosylated haemoglobin (HbA1c)</outcome>
      <timepoint>Weeks 0-52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting plasma glucose (FPG)</outcome>
      <timepoint>Weeks 0-52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Male or female, age 18 years or older at the time of signing inform consent

          -  Body mass index (BMI) equal or above 30.0 kg/m^2 at the screening visit

          -  At least one unsuccessful weight loss attempt per investigator judgement</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  A HbA1c (glycosylated haemoglobin) equal to or above 6.5% at screening or diagnosed
             with type 1 or type 2 diabetes mellitus

          -  Treatment with glucose lowering agent(s) within 90 days before screening

          -  Screening calcitonin equal to or above 50 ng/L (pg/mL)

          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine
             neoplasia syndrome type 2

          -  History of pancreatitis (acute or chronic)

          -  Obesity induced by endocrine disorders (e.g. Cushing Syndrome)

          -  Treatment with any medication within 90 days before screening that based on
             investigator's judgement may cause significant weight change

          -  Previous surgical treatment for obesity (liposuction and/or abdominoplasty performed 1
             year before screening is allowed)

          -  History of major depressive disorder within 2 years before randomisation

          -  Any lifetime history of a suicidal attempt

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             childbearing potential and not using an adequate contraceptive method (adequate
             contraceptive measures as required by local regulation or practice)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>957</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>12/04/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Camperdown</hospital>
    <hospital>Novo Nordisk Investigational Site - Merewether</hospital>
    <hospital>Novo Nordisk Investigational Site - St Leonards</hospital>
    <hospital>Novo Nordisk Investigational Site - Heidelberg West</hospital>
    <hospital>Novo Nordisk Investigational Site - Melbourne</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2291 - Merewether</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>3081 - Heidelberg West</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Li√®ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Mons</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duisburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>St. Ingbert</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Stuttgart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar-Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah-Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Penza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Tumen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Voronezh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Luton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Norwich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Rotherham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted globally. The aim of this trial is to investigate safety and efficacy
      of once-daily semaglutide in obese subjects without diabetes mellitus.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02453711</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>